Androgen Receptor Expression in ER and PR Negative Breast Cancer—A Study from a Tertiary Hospital in Northern India

 

 Permissions and Reprints

Abstract

Objectives Breast cancer is the leading cause of cancer-related deaths in women. Estrogen (ER) and progesterone receptor (PR) status and Her2 overexpression are major determinants in therapeutic decision making. Triple-negative breast cancers (TNBCs) have limited treatment options. Androgen receptor (AR) expression opens up therapeutic avenues for these patients. The aim of this article was to study the immunohistochemical expression of ARs in ER and PR Negative breast carcinomas and to correlate AR expression with various clinical, histopathological, and other immunohistochemical parameters.

Materials and Methods It is a cross-sectional study including 105 ER and PR Negative cases of breast carcinoma. Clinical parameters, histopathology, and immunohistochemical expression of AR, Her2, and Ki67 were analyzed in all cases.

Results AR expression was observed in 63.8% of ER and PR Negative breast cancers. In this group, AR expression was strongly associated with Her2 co-expression (89.2%) as compared to TNBCs (45.8%); p-value = 0.0002. Significant correlation was also observed between AR expression and tumor necrosis (p-value = 0.034) and postmenopausal status (p = 0.007).

Conclusion Our study shows that significant proportion of ER and PR Negative breast carcinomas (ER- PR- Her2+ and TNBCs) show AR expression. We strongly recommend routine evaluation of all hormone receptor-negative breast carcinomas for AR status by immunohistochemistry.

Authors' Contributions

Kanwardeep Kwatra, Pamela Alice Kinsley, and Sumeet Sidhu helped in planning and conceptualization and designing. Sumeet Sidhu and Kanwardeep Kwatra conducted and reported the study and analyzed and interpreted the data. Sumeet Sidhu acquired the data.

Publication History

Article published online:
29 May 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

• References

• 1 GLOBOCAN 2020: Cancer incidence and mortality statistics worldwide and by region [Internet]. IARC WHO 2020 . [cited 2021 November 25]. Accessed April 19, 2023 at: https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf
  PubMedGoogle Scholar
• 2 Dai X, Xiang L, Li T, Bai Z. Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer 2016; 7 (10) 1281-1294
  CrossrefPubMedGoogle Scholar
• 3 Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol 2014; 5 (03) 382-392
  CrossrefPubMedGoogle Scholar
• 4 Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol 2010; 23 (Suppl. 02) S52-S59
  CrossrefPubMedGoogle Scholar
• 5 Piccart-Gebhart MJ, Procter M, Leyland-Jones B. et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353 (16) 1659-1672
  CrossrefPubMedGoogle Scholar
• 6 Tang P, Tse GM. Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 Update. Arch Pathol Lab Med 2016; 140 (08) 806-814
  CrossrefPubMedGoogle Scholar
• 7 Liao J, Gallas M, Pegram M, Slingerland J. Lapatinib: new opportunities for management of breast cancer. Breast Cancer (Dove Med Press) 2010; 2: 79-91
  Google Scholar
• 8 Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther 2019; 199: 30-57
  CrossrefPubMedGoogle Scholar
• 9 Schick J, Ritchie RP, Restini C. Breast cancer therapeutics and biomarkers: past, present, and future approaches. Breast Cancer (Auckl) 2021; 15: 1178223421995854
  Google Scholar
• 10 Iacopetta D, Rechoum Y, Fuqua SA. The role of androgen receptor in breast cancer. Drug Discov Today Dis Mech 2012; 9 (1-2): e19-e27
  CrossrefPubMedGoogle Scholar
• 11 Sutton LM, Cao D, Sarode V. et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol 2012; 138 (04) 511-516
  CrossrefPubMedGoogle Scholar
• 12 Lehmann BD, Bauer JA, Chen X. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121 (07) 2750-2767
  CrossrefPubMedGoogle Scholar
• 13 Bozovic-Spasojevic I, Zardavas D, Brohée S. et al. The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data. Clin Cancer Res 2017; 23 (11) 2702-2712
  CrossrefPubMedGoogle Scholar
• 14 Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011; 24 (07) 924-931
  CrossrefPubMedGoogle Scholar
• 15 Vera-Badillo FE, Templeton AJ, de Gouveia P. et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106 (01) djt319
  CrossrefPubMedGoogle Scholar
• 16 Lakis S, Kotoula V, Eleftheraki AG. et al. The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. Breast 2014; 23 (03) 234-243
  CrossrefPubMedGoogle Scholar
• 17 Lim E, Ni M, Cao S, Hazra A, Tamimi RM, Brown M. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Curr Breast Cancer Rep 2014; 6 (02) 71-78
  CrossrefPubMedGoogle Scholar
• 18 Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch 2010; 457 (04) 467-476
  CrossrefPubMedGoogle Scholar
• 19 Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003; 120 (05) 725-731
  CrossrefPubMedGoogle Scholar
• 20 Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?. Am J Cancer Res 2014; 4 (04) 353-368
  PubMedGoogle Scholar
• 21 Park S, Koo JS, Kim MS. et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 2011; 22 (08) 1755-1762
  CrossrefPubMedGoogle Scholar
• 22 Peters AA, Buchanan G, Ricciardelli C. et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009; 69 (15) 6131-6140
  CrossrefPubMedGoogle Scholar
• 23 Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008; 10 (06) 542-548
  CrossrefPubMedGoogle Scholar
• 24 Ni M, Chen Y, Fei T. et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev 2013; 27 (07) 734-748
  CrossrefPubMedGoogle Scholar
• 25 Gerratana L, Basile D, Buono G. et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev 2018; 68: 102-110
  CrossrefPubMedGoogle Scholar
• 26 Wardley A, Cortes J, Provencher L. et al. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Res Treat 2021; 187 (01) 155-165
  CrossrefPubMedGoogle Scholar